ULTRAGENYX PHARMACEUTICAL INC. Foreign Currency Transaction Gain (Loss), before Tax
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Foreign Currency Transaction Gain (Loss), before Tax of $221.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-12.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2021-02-12
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-12-31 was $388.00K, a 63.71% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-09-30 was -$142.00K.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-06-30 was $449.00K, a 1940.91% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for the quarter ending 2020-03-31 was -$474.00K.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for fiscal 2020 was $221.00K.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for fiscal 2019 was -$688.00K.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for fiscal 2018 was -$5.31M, a 175.65% decline from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. foreign currency transaction gain (loss), before tax for fiscal 2017 was $7.02M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $246.00K derived: sum of 2 quarters · filed 2021-02-12 | $695.00K derived: sum of 3 quarters · filed 2021-02-12 | $221.00K 10-K · filed 2021-02-12 |
| 2020-09-30 | -$142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $307.00K derived: sum of 2 quarters · filed 2020-10-27 | -$167.00K 10-Q · filed 2020-10-27 | $70.00K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-06-30 | $449.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$25.00K 10-Q · filed 2020-07-30 | $212.00K derived: sum of 3 quarters · filed 2021-02-12 | -$146.00K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-03-31 | -$474.00K 10-Q · filed 2020-05-07 | -$237.00K derived: sum of 2 quarters · filed 2021-02-12 | -$595.00K derived: sum of 3 quarters · filed 2021-02-12 | -$573.00K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$121.00K derived: sum of 2 quarters · filed 2021-02-12 | -$99.00K derived: sum of 3 quarters · filed 2021-02-12 | -$688.00K 10-K · filed 2021-02-12 |
| 2019-09-30 | -$358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$336.00K derived: sum of 2 quarters · filed 2020-10-27 | -$925.00K 10-Q · filed 2020-10-27 | -$381.00K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$567.00K 10-Q · filed 2020-07-30 | -$23.00K derived: sum of 3 quarters · filed 2021-02-12 | -$30.00K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-03-31 | -$589.00K 10-Q · filed 2020-05-07 | -$45.00K derived: sum of 2 quarters · filed 2021-02-12 | -$52.00K derived: sum of 3 quarters · filed 2021-02-12 | -$1.13M derived: sum of 4 quarters · filed 2021-02-12 |
| 2018-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $537.00K derived: sum of 2 quarters · filed 2021-02-12 | -$536.00K derived: sum of 3 quarters · filed 2021-02-12 | -$5.31M 10-K · filed 2021-02-12 |
| 2018-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$1.08M derived: sum of 2 quarters · filed 2019-11-06 | -$5.85M 10-Q · filed 2019-11-06 | -$7.27M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-06-30 | -$1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$5.85M 10-Q · filed 2019-08-02 | -$7.26M derived: sum of 3 quarters · filed 2020-02-14 | -$3.43M derived: sum of 4 quarters · filed 2020-02-14 |
| 2018-03-31 | -$4.77M 10-Q · filed 2019-05-07 | -$6.19M derived: sum of 2 quarters · filed 2020-02-14 | -$2.36M derived: sum of 3 quarters · filed 2020-02-14 | $1.60M derived: sum of 4 quarters · filed 2020-02-14 |
| 2017-12-31 | -$1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $2.41M derived: sum of 2 quarters · filed 2020-02-14 | $6.37M derived: sum of 3 quarters · filed 2020-02-14 | $7.02M 10-K · filed 2020-02-14 |
| 2017-09-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $7.78M derived: sum of 2 quarters · filed 2018-11-06 | $8.43M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $4.60M 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | $648.00K 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$1.32M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |